Alzheimer’s Drug Development: What’s Possible on the Path to 2025? (Video)

Preventing or effectively treating Alzheimer’s disease (AD) by 2025. That’s the heady goal put forth a few years ago by global leaders and the U.S. government. The well-documented sluggishness of contemporary drug development is a leading obstacle, so an international group of AD experts recently drafted a prominent paper in Alzheimer’s Research & Therapy that they dub “the path to 2025.” Their aim is to lay out “what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies.”

In this five-minute video, the paper’s lead author, Jeffrey Cummings, MD, ScD, Director of Cleveland Clinic Lou Ruvo Center for Brain Health, shares key takeaways from the paper and strategies for speeding success in AD therapeutics over the next nine years.